Articles in this Issue
Greg Flyte
The biopharmaceutical industry continues to grow at
a healthy pace, with the biosimilars market predicted
to expand even more rapidly. As biologic drugs become more complex, biosimilars become more important, and downward cost pressures from both governments and payers increase, biopharmaceutical manufacturers are turning more often to custom service providers to assist in the development and manufacture of biotherapeutics.
Cynthia A. Challener Ph.D.
Everyone in the pharmaceutical industry value chain
—equipment suppliers, small-molecule and biologic
custom development and manufacturing service providers, companies providing support for clinical trials, and drug manufacturers—is working toward one overarching goal: delivery life-saving medicines to the patients who need them.
Stephen A. Munk
New drugs in the United States must receive a marketing authorization from the Food and Drug Administration (FDA) before they can be marketed to healthcare providers and patients on the open market.
Kevin Haehl
Numerous changes are occurring in the pharmaceutical industry today. Drug manufacturers face significant pressure to reduce costs from governments, insurers, and patients.
Zaher El-Assi
Testing new potential drugs to confirm their efficacy
and safety is a crucial part of the drug development
process. Clinical trials provide invaluable information
regarding the performance of drug candidates, but are
also time-consuming and costly.
Larry Kadis
The pharmaceutical industry has been undergoing significant change in recent years. Governments and insurance companies (payers) are looking for proof that new medicines provide value for their money.